Based in Ennis since 1974, Vitalograph is a global leader in the development and production of respiratory diagnostic devices. With exports to more than 110 countries worldwide, they are now growing their presence in the Gulf Region with new partnerships in Saudi Arabia, Jordan, Kuwait, and the UAE.
Their recent participation at Arab Health, the leading medical industry exhibition in the Middle East, has firmly placed them amongst the Irish innovators paving the way for the future of healthcare in this region.
As part of Enterprise Ireland’s delegation of 20 top Irish medtech companies, Vitalograph showcased their product range to over 50,000 visitors and forged relationships with many new partners.
Speaking of the event, Vitalograph CEO Frank Keane said: “The Gulf Region represents a real potential for our company as there is a high incidence of COPD and Asthma, which are two of the diseases that our diagnostic devices address. We have received superb support from the team at Enterprise Ireland whilst at Arab Health, and they introduced us to many potential partners which we are very excited about.”
2022 is set to be a busy year for Vitalograph, with plans to increase their workforce in Ennis and to create a new base in Limerick to meet the growing demand for their best-in-class respiratory diagnostic products and services. They are widely recognized as the ‘go-to people’ for respiratory diagnostics due to the accuracy of their devices which feature Fleisch-flow measurement technology, and the integrity of their services. Vitalograph also provides a full suite of services to companies around the world conducting clinical drug trial studies.
Speaking about this year’s plans for expansion Mr Keane said: “Vitalograph is in the enviable position of needing to expand to cope with the growing demand for our products and services. We have an extremely dedicated workforce in Ennis, many of whom have been with us for more than a decade, and we are looking forward to growing our local team significantly in the coming months, bringing a range of career opportunities to suit all levels of experience and qualifications.”
As the world faces a renewed focus on respiratory-related healthcare issues post-COVID, demand for Vitalograph’s range of spirometry devices is on the increase. A significant milestone for the company is having recently received FDA approval for the ALPHA, their premium desktop spirometer. This approval allows the ALPHA to be marketed throughout the United States and is expected to drive demand for all of the company’s spirometry products in the rapidly growing USA respiratory care market, where Vitalograph has had a presence since 1969.
